Recent research indicates that CDC42 plays a role in the pathogenesis of kidney disorders such as congenital nephrotic syndrome or glomerulosclerosis because it is necessary for the correct function of renal podocyte and tubule.
Recent findings suggest gut microbiota dysbiosis may be behind the inflammation in diabetic nephropathy (DN), the leading cause of end-stage renal disease (ESRD).
Shanghai Micurx Pharmaceutical Co. Ltd. has discovered peptide-drug conjugates consisting of peptide-targeting kidney cells covalently linked to anti-inflammatory or immunomodulating or nephron-protective drugs through linkers reported to be useful for the treatment of acute kidney injury, nephritis, chronic kidney disease, chronic glomerulonephritis, diabetic nephropathy and systemic lupus erythematosus, among others.
Acute kidney injury (AKI) is a common disease with high morbidity that still lacks effective drug treatments. The death of tubular epithelial cells is the principal basis for AKI. This cell death in AKI does not occur by necrosis but by other cell death mechanisms such as pyroptosis, among others. Recent findings have implicated chromodomain Y-like (CDYL) in autosomal dominant polycystic kidney disease, but its role in AKI has not been established.
More than 18 months after announcing plans to spin off its kidney care division as a standalone public company, Baxter International Inc. reached an agreement to sell the business for $3.8 billion to global equity investor Carlyle and Atmas Health instead. The transaction is expected to close in late 2024 or the first quarter of 2025.
The U.S. FDA has granted accelerated approval to Novartis AG’s Fabhalta (iptacopan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. The approval strengthens the company’s renal disease presence as it puts two other IgAN treatments through clinical trials.
Meta Pharmaceuticals Inc. announced that the FDA has granted rare pediatric disease designation to its investigational new drug META-001-PH for the treatment of primary hyperoxaluria (PH), an autosomal recessive metabolic disorder in which oxalate is overproduced and deposited in the body.
An antibody that binds to the latent form of transforming growth factor-β1 (TGF-β1) prevented its release into the extracellular matrix and reduced the progression of fibrosis in the kidney. TGF-β is synthesized and secreted into the extracellular matrix in a latent inactive form associated with the latency peptide.
Renalys Pharma Inc. completed a ¥6 billion (US$38.199 million) series A round that will enable it to complete a phase III trial for sparsentan for immunoglobulin A nephropathy (IgAN) in Japan. Tokyo-based Renalys in-licensed rights to sparsentan in January 2024 from Travere Therapeutics Inc. to develop the compound in Japan and 13 Asian countries to treat IgAN, a rare kidney disease.
RSS
